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Abstract
Changes in two novel HBV serological markers, linearized hepatitis B surface antigen (HQ-HBsAg) and hepatitis B core-related antigen
(HBcrAg), in the natural history of chronic hepatitis B (CHB) have not been well characterized. Serum HQ-HBsAg and HBcrAg levels of 404
Asian treatment-na€ıve CHB patients were analysed in a cross-sectional manner. Patients were categorized into ﬁve groups: immune tolerant
(IT group, n = 52), immune clearance (IC group, n = 105), hepatitis B e antigen (HBeAg)-negative hepatitis (ENH group, n = 97),
HBeAg-negative quiescent group (ENQ group, n = 95) and CHB with hepatitis B surface antigen (HBsAg) seroclearance (SC group, n = 55).
HQ-HBsAg and HBcrAg were measured and correlated with HBV DNA, HBsAg, HBV genotype and clinical parameters. HQ-HBsAg
showed good correlation with HBsAg, especially in the ENQ group (r = 0.874, p <0.001). Correlation of HQ-HBsAg with HBV DNA was
less prominent and weakest in the ENH group (r = 0.268, p 0.008). HBcrAg correlated best with HBV DNA in the ENQ group (r = 0.537,
p <0.001). In the ENQ group, 42.1% of patients had undetectable HBcrAg; this subgroup of patients, when compared with those with
detectable HBcrAg, had signiﬁcantly lower median HBV DNA (3.17/4.48 log IU/mL, p <0.001) and HBsAg (5.05/5.96 log mIU/mL, p <0.001)
levels. Forty per cent of the SC group patients had detectable HQ-HBsAg and/or HBcrAg up to 42 months after HBsAg seroclearance.
When comparing anti-HBs positivity and median time after HBsAg seroclearance in the SC group with and without detectable HQ-HBsAg/
HBcrAg, there was no signiﬁcant difference (22.7% and 36.4%, respectively, p 0.284, and 76.5 and 93.2 months, respectively, p 0.245).
HQ-HBsAg and HBcrAg showed unique patterns of distribution throughout the ﬁve disease phases of CHB, including high detectability rates
after HBsAg seroclearance, opening up different possibilities for their applicability.
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Introduction
Chronic hepatitis B (CHB) affects 350–400 million individuals
worldwide, of which 15–40% will develop cirrhosis and its
complications, including hepatocellular carcinoma (HCC) [1].
Disease activity is reﬂected by serum hepatitis B virus (HBV)
DNA levels. Serum HBV DNA >20 000 IU/mL, when
compared with undetectable HBV DNA levels, increases
the risk of cirrhosis and HCC by ten- and nine-fold,
respectively [2,3]. Another biomarker advocated for the
disease monitoring of CHB is the quantiﬁcation of serum
hepatitis B surface antigen (HBsAg). Serum HBsAg levels have
been demonstrated to play a role in predicting CHB patients
with quiescent disease activity [4,5], risk of cirrhosis and
HCC [5,6], insigniﬁcant liver ﬁbrosis [7], and subsequent
HBsAg seroclearance [8].
The current lower detection limit for the majority of
conventional serum HBsAg assays is 50 mIU/mL. When serum
HBsAg falls into the undetectable range in CHB patients, HBV
could still persist at low replicative and transcriptional levels
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[9]. In addition, conventional HBsAg assays target only one
HBsAg epitope, the common determinant ‘a’. Mutations within
the determinant ‘a’ can give false-negative results [10]. An
emerging viral marker is the linearized HBsAg (HQ-HBsAg),
which targets both the outer determinant ‘a’ of the surface
genome and the epitope embedded inside the lipid bilayer of
the viral envelope, with detection enhanced by adding
detergents to the reaction buffer and by improving the assay
tracer [11]. The HQ-HBsAg assay may therefore detect
HBsAg mutants more effectively and achieve an even lower
limit of detection of 5 mIU/mL [12]. Another potentially useful
novel marker is the hepatitis B core-related antigen (HBcrAg),
which detects an identical amino-acid sequence shared by the
hepatitis B e antigen (HBeAg), hepatitis B core antigen and
22 kDa precore protein; production of this sequence is not
dependent on HBV DNA formation [13]. Serum HBcrAg
correlates with disease activity [14] and could also play a role
in predicting HCC development [15].
Our previous study demonstrated that the combined use of
HBcrAg and HQ-HBsAg could detect HBV in >40% of CHB
patients after HBsAg seroclearance [16]. We now proceed to
determine the serum HQ-HBsAg and HBcrAg titres in
different disease phases of CHB and correlate them with
established viral markers including serum HBV DNA and
HBsAg in a large cohort of Asian CHB patients.
Methods
Patients
The present patient cohort was recruited from the Liver
Clinic, Department of Medicine, The University of Hong
Kong, Queen Mary Hospital, Hong Kong, from March 2010
to July 2013. All enrolled Asian CHB patients were
treatment-na€ıve and had no evidence of concomitant liver
disease, including chronic hepatitis C virus infection or
signiﬁcant intake of alcohol (20 g per day for women, 30 g
per day for men). The patient cohort was divided into ﬁve
groups: immune tolerant phase (IT group) (i.e. HBeAg-posi-
tive with normal alanine aminotransferase) (ALT); immune
clearance phase (IC group) (i.e. HBeAg-positive with elevated
ALT, HBeAg-negative hepatitis with elevated ALT) (ENH
group), HBeAg-negative quiescent phase with normal ALT
(ENQ group), and known CHB with documented HBsAg
seroclearance (SC group). For the ﬁrst four groups, all
patients were positive, with HBsAg for at least 6 months
prior to enrollment. For the SC group, patients had
HBsAg-positivity documented at our clinic for at least
6 months and had undergone HBsAg seroclearance upon
follow-up, and were then persistently HBsAg-negative with or
without appearance of antibody to HBsAg (anti-HBs) for at
least 6 months. HBsAg seroclearance was documented by the
conventional HBsAg assay with the lower limit of detection
<50 mIU/mL.
The upper limit of normal of ALT was set at 40 U/L.
Patients enrolled into either the IT group or ENQ group had
persistently normal ALT for 6 months prior to enrollment.
Plasma samples were stored at 20°C until tested. This study
was approved by the Institutional Review Board, the University
of Hong Kong and West Cluster of Hospital Authority, Hong
Kong.
Serum HQ-HBsAg
Serum HQ-HBsAg was measured using a chemiluminscent
enzyme immunoassay (CLEIA) Lumipulse G1200 automated
analyzer (Fujirebio Inc, Tokyo, Japan) as previously described
[11]. Brieﬂy, plasma samples with denatured HBsAg were
added to ferrite microparticles bound with anti-HBs mono-
clonal antibodies against the external determinant ‘a’ and the
internal (normally embedded) bilipid layer epitope. After
washing and incubation, 200 lL of substrate (AMPPD;
3-(20-spiroadamantan)-4-methoxy-4-(3″-phosphoryloxy) phe-
nyl-1, 2-dioxetane disodium salt) (Applied Biosystems, Bed-
ford, MA, USA) was added. The relative intensity of
chemiluminescence was measured and the concentration of
HBsAg calculated by comparing with a standard curve. The
dynamic range of HQ-HBsAg was 5–150 000 mIU/mL (0.70–
5.18 log mIU/mL), and retesting was performed with a
200-fold dilution of samples among >150 000 mIU/mL as
recommended [12].
Serum HBcrAg
Serum HBcrAg was measured using CLEIA as described
previously [14]. Brieﬂy, sodium dodecyl sulphate pretreated
serum was incubated with monoclonal antibodies against
denatured HBcAg and HBeAg. After washing and incubation,
the relative chemiluminescence intensity was measured and
the HBcrAg concentration was calculated by comparison with
a standard curve generated from known concentrations of
recombinant HBeAg-containing peptides. The lower detection
limit was 100 U/mL (2 log U/mL).
Other laboratory assays
Serum HBV DNA and HBsAg levels were measured using the
Cobas Taqman assay (Roche Diagnostics, Branchburg, NJ,
USA) and Elecsys HBsAg II assay (Roche Diagnostics, Gmbh,
Mannheim, Germany), respectively, with a lower limit of
detection of 20 IU/mL and 50 mIU/mL, respectively. HBV
genotyping was performed using the INNO-LIPA HBV geno-
typing assay (Innogenetics, Ghent, Belgium).
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Statistical analyses
Continuous variables were expressed as median (range). All
serum viral marker results were expressed in logarithm.
Statistical analyses were performed using SPSS version 19.0
(SPSS Inc, Chicago, IL, USA). The Mann–Whitney U-test or the
Kruskal–Wallis test when appropriate, was used for compar-
ison of continuous variables. The chi-square test was used for
comparing categorical variables. Correlation between different
clinical parameters was tested using Spearman’s bivariate
correlation. A two-sided p value of <0.05 was considered
statistically signiﬁcant.
Results
Four hundred and four treatment-na€ıve Asian CHB patients
were recruited. The baseline patient characteristics as
stratiﬁed by their grouping are presented in Table 1.
Fifty-two (12.9%), 105 (26.0%), 95 (23.5%) and 97 (24.0%)
patients were enrolled into the IT, IC, ENQ and ENH
groups, respectively. We also enrolled 55 (13.6%) CHB
patients with HBsAg seroclearance achieved (SC group).
These 55 patients were HBsAg-positive in our clinic for a
median duration of 80.7 (range, 24.6–262.2) months
before HBsAg seroclearance, and were then tested at a
median 19.1 (range, 6.2–42.7) months after HBsAg seroclea-
rance, with 17 (30.9%) anti-HBs-positive at the time of
testing.
The distribution of serum HBV DNA and HBsAg levels in all
ﬁve groups is depicted in Fig. 1(a–b). The IT group had the
highest median HBV DNA and HBsAg levels, followed by the
IC, ENH and then the ENQ group.
Serum HQ-HBsAg and HBcrAg levels among the whole
cohort
Among the whole patient cohort (n = 404), there was a strong
correlation between HQ-HBsAg levels and HBV DNA, HBsAg
and HBcrAg levels (r = 0.762, 0.804 and 0.818, respectively, all
p <0.001). Serum HBcrAg levels also correlated strongly with
HBV DNA and HBsAg levels (r = 0.854 and 0.703, respec-
tively, p <0.001). A weaker correlation was seen between
HQ-HBsAg and HBcrAg levels with ALT (r = 0.210 and 0.341,
respectively, p <0.001). Both HQ-HBsAg and HBcrAg had a
moderate inverse correlation with age (r = 0.549 and
0.555, respectively, p <0.001).
When comparing median HBsAg and HQ-HBsAg levels
among the whole patient cohort, there was no signiﬁcant
difference noted (6.22 and 6.31 log mIU/mL, respectively,
p 0.411).
HBeAg-positive disease
The median HQ-HBsAg and HBcrAg levels and their distribu-
tion in HBeAg-positive disease are depicted in Table 1 and in
Fig. 1(c,d). For HQ-HBsAg, the IT group had signiﬁcantly
higher median levels than the IC group (7.75 and 7.01 log IU/
mL, respectively, p <0.001). Although HQ-HBsAg correlated
well with HBsAg for both the IT and IC groups (Table 2A and
Fig. S1, r = 0.639 and 0.503, respectively, p <0.001), median
HQ-HBsAg levels were signiﬁcantly higher than median HBsAg
levels for both groups (IT group, 7.75 and 7.49 log mIU/mL,
respectively, p 0.008; IC group, 7.01 and 6.72 log mIU/mL,
respectively, p 0.021). No correlation exists between
HQ-HBsAg and ALT (Table 2A).
Median HBcrAg levels in the IT group were also signiﬁcantly
higher than in the IC group (8.54 and 7.92 log U/mL,
TABLE 1. Baseline characteristics of all 404 patients
All patients
(n = 404)
HBeAg-positive (n = 157) HBeAg-negative (n = 192)
SC group
(n = 55)
IT group
(n = 52)
IC group
(n = 105)
ENH group
(n = 97)
ENQ group
(n = 95)
Age, years 46.4 (20.8–82.3) 30.4 (24.4–74.0) 37.2 (20.8–65.6) 49.6 (24.8–67.4) 52.0 (24.0–80.4) 52.5 (28.4–82.3)
Male, n (%) 267 (58.3) 29 (55.8) 67 (63.8) 65 (67.0) 65 (68.4) 41 (74.5)
Genotypea
B, n (%) 208 (51.5) 30 (57.7) 40 (38.1) 38 (39.2) 63 (66.3) 37 (67.3)
C, n (%) 196 (48.5) 22 (42.3) 65 (61.9) 59 (60.8) 32 (33.7) 18 (32.7)
Albumin, g/L 43 (25–50) 44 (43–46) 41 (25–50) 42 (29–48) 44 (33–49) 44 (34–50)
Bilirubin, lM 12 (2–94) 10 (4–29) 13 (2–52) 13 (4–94) 11 (4–50) 10 (2–38)
ALT, U/L 47 (5–2144) 23 (9–39) 130 (41–2144) 93 (44–2083) 28 (22–34) 23 (4–60)
HBV DNA, log IU/mL 5.99 (UD–9.53) 8.29 (2.15–8.92) 7.68 (3.95–9.53) 6.05 (3.12–8.60) 3.82 (UD–7.12) UD (UD–2.09)
HBsAg, log mIU/mL 6.22 (UD–8.89) 7.49 (3.87–8.89) 6.72 (3.10–8.88) 6.14 (3.39–7.98) 5.60 (1.83–7.19) UD
HQ-HBsAg, log mIU/mL 6.31 (UD–9.06) 7.75 (4.40–9.06) 7.01 (3.03–8.47) 5.93 (1.06–7.59) 5.71 (2.59–7.11) UD (UD–1.20)
HBcrAg, log U/mL 5.24 (UD–9.92) 8.54 (3.01–9.00) 7.92 (5.04–9.92) 4.92 (2.47–7.69) 2.60 (UD–3.71) UD (UD–8.39)
UD, undetectable; HBsAg, hepatitis B surface antigen; HQ-HBsAg, linearized HBsAg; HBcrAg, hepatitis B core-related antigen; IT group, immune-tolerant group; IC group,
immune-clearance group; ENH group, HBeAg-negative hepatitis group; ENQ group, HBeAg-negative quiescent group; SC group, chronic hepatitis B with HBsAg seroclearance.
Lower limit of detection: HBV DNA, 1.30 log IU/mL; HBsAg, 1.70 log IU/mL; HQ-HBsAg, 0.70 log IU/mL; HBcrAg, 2 log U/mL.
aGenotype in patients with very low or undetectable viral loads (e.g. the SC group) was determined using a previously stored plasma sample of higher viral load.
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(a)
(b)
(c)
(d)
FIG. 1. Distribution of serum HBV DNA (a), serum HBsAg (b), serum HQ-HBsAg (c) and serum HBcrAg (d) levels among different disease phases
of CHB. The top and bottom of each box represent the 25th and 75th percentile interval. The line through the box represents the median. The error
bars are the 5th and 95th percentile intervals. Outliers are represented by asterisks. HQ-HBsAg, linearized HBsAg; HBcrAg, hepatitis B core-related
antigen; LLD, lower limit of detection. IT group, immune-tolerant group; IC group, immune-clearance group; ENH group, HBeAg-negative hepatitis
group; ENQ group, HBeAg-negative quiescent group; SC group, chronic hepatitis B with HBsAg seroclearance.
TABLE 2. Correlation of HQ-HBsAg (2A) and HBcrAg (2B) with different patient characteristics among different patient groups
IT group (n = 52) IC group (n = 105) ENH group (n = 97) ENQ group (n = 95)
r p r p r p r p
(A) HQ-HBsAg
Age (years) 0.084 0.554 0.072 0.483 0.208 0.033 0.168 0.104
HBV DNA (log IU/mL) 0.520 <0.001 0.268 0.008 0.427 <0.001 0.442 <0.001
HBsAg (log mIU/mL) 0.639 <0.001 0.541 <0.001 0.503 <0.001 0.874 <0.001
HBcrAg (log U/mL) 0.401 0.003 0.605 <0.001 0.596 <0.001 0.401 <0.001
ALT (U/L) 0.076 0.598 0.020 0.848 0.150 0.128 0.112 0.284
IT group (n = 52) IC group (n = 105) ENH group (n = 97) ENQ group (n = 95)
r p r r p p r p
(B) HBcrAg
Age (years) 0.110 0.438 0.401 0.013 0.901 <0.001 0.019 0.851
HBV DNA (log IU/mL) 0.369 0.007 0.484 0.537 <0.001 <0.001 0.472 <0.001
HBsAg (log mIU/mL) 0.286 0.040 0.406 0.245 0.017 <0.001 0.388 <0.001
HQ-HBsAg (log mIU/mL) 0.401 0.003 0.596 0.401 <0.001 <0.001 0.605 <0.001
ALT (U/L) 0.102 0.476 0.145 0.272 0.008 0.140 0.076 0.457
HBsAg, hepatitis B surface antigen; HQ-HBsAg, linearized HBsAg; HBcrAg, hepatitis B core-related antigen; ALT, alanine aminotransferase; IT group, immune-tolerant group; IC
group, immune-clearance group; ENH group, HBeAg-negative hepatitis group; ENQ group, HBeAg-negative quiescent group.
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respectively, p <0.001). The correlation of HBcrAg with other
viral markers is depicted in Table 2(B). Correlation of HBcrAg
with HBV DNA was moderate (IT group, r = 0.369, p 0.007;
IC-group, r = 0.484, p <0.001). The pattern of HBcrAg
distribution in HBeAg-positive disease is very similar to HBV
DNA, as depicted in Fig. S2: very leptokurtic in the IT group
(interquartile range 0.22 log U/mL, z = 28.3, and interquartile
range 0.25 log IU/mL, z = 34.1, respectively, Fig. S2a) but
more mesokurtic in the IC group (Fig. S2b). No correlation
exists between HBcrAg and ALT (Table 2B).
HBeAg-negative disease
The median HQ-HBsAg and HBcrAg levels and their distribu-
tion in HBeAg disease are depicted in Table 1 and Fig. 1(c–d).
For HQ-HBsAg, median levels in the ENQ group are
signiﬁcantly lower than in the ENH group (5.71 and
5.93 log IU/mL, respectively, p 0.005). Unlike HBeAg-positive
disease, there was no signiﬁcant difference between median
HQ-HBsAg and HBsAg levels for both groups (ENQ group,
5.71 and 5.60 log mIU/mL, p 0.719; ENH group, 5.93 and
6.14 log mIU/mL, p 0.172). As depicted in Table 2(A), serum
HQ-HBsAg correlated best with HBsAg in the ENQ group
(r = 0.874, p <0.001). Correlation between HQ-HBsAg and
HBV DNA was weaker, especially in the ENH group
(r = 0.268, p 0.008). No correlation exists between
HQ-HBsAg and ALT.
The median HBcrAg level in the ENQ group was signiﬁ-
cantly lower than that in the ENH group (2.60 and 4.92 log U/
mL, respectively, p <0.001). Forty patients (42.1%) in the ENQ
group had undetectable HBcrAg. This subgroup of patients,
when compared with the ENQ group patients with detectable
HBcrAg, had signiﬁcantly lower median HBV DNA (3.17 and
4.48 log IU/mL, respectively, p <0.001), HBsAg (5.05 and
5.96 log mIU/mL, respectively, p <0.001) and HQ-HBsAg
(5.03 and 6.05 log mIU/mL, respectively, p 0.012). Concerning
the correlation of HBcrAg with other clinical parameters,
HBcrAg correlated best with HBV DNA in the ENQ group
(r = 0.537, p <0.001) and correlated best with HQ-HBsAg in
the ENH group (r = 0.605, p <0.001). HBcrAg distribution in
HBeAg-negative patients, as with the IC group patients
with HBeAg-positive disease, had a mesokurtic distribution
(Fig. S2).
HQ-HBsAg and HBcrAg after HBsAg seroclearance
The percentage of detectable serum HQ-HBsAg and HBcrAg
in the SC group patients (n = 55) is depicted in Fig. 2(a).
Sixteen (29.1%) and 12 (21.8%) had detectable HQ-HBsAg and
HBcrAg, respectively, with the median duration after HBsAg
seroclearance in these two groups being 16.2 (range 6.2–42)
months and 19.2 (range 6.6–38.3) months, respectively. Only
one patient (1.8%) had detectable HBV DNA. The levels of
detectable HQ-HBsAg and HBcrAg with respect to the time of
HBsAg seroclearance are depicted in Fig. 2(b). The median
levels of detectable HQ-HBsAg and HBcrAg in the SC group
were 1.18 (range 0.72 – 8.16) log mIU/mL and 2.70 (range 2.30
– 8.39) log U/mL, respectively.
Altogether, 22 patients (40%) had detectable viral protein
markers after HBsAg seroclearance. When comparing patients
having either one or both detectable viral proteins (n = 22)
with patients without detectable HQ-HBsAg and HBcrAg
(n = 33), there was no signiﬁcant difference in anti-HBs
positivity (22.7% and 36.4%, respectively, p 0.284) or in the
median duration after HBsAg seroclearance (76.5 and
93.2 months, respectively, p 0.245).
Discussion
Our present study provides the ﬁrst detailed description of
HQ-HBsAg and HBcrAg titres in a large cohort of Asian
(a)
(b)
FIG. 2. Percentage of detectable viral markers in all 55 patients in the
SC group (a) and levels of HQ-HBsAg and HBcrAg in 22 SC-group
patients with detectable viral markers (b). SC group, chronic hepatitis
B with HBsAg seroclearance. (b) Serum HQ-HBsAg represented by
asterisks, serum HBcrAg represented by triangles. Lower limit of
detection: HBsAg, 50 mIU/mL; HQ-HBsAg, 5 mIU/mL (0.7 log mIU/
mL); HBcrAg, 100 U/mL (2 log U/mL).
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treatment-na€ıve CHB patients, and underlines the possible
roles that both novel serologic markers could play in the
disease monitoring of CHB (Table 3).
The role of quantitative serum HBsAg measurements in
the management of CHB is continuously expanding [4–8],
including during peginterferon [17] and nucleos(t)ide analogue
(NA) therapy [18,19]. Besides showing strong correlation
with serum HBsAg, the correlation of HQ-HBsAg with HBV
DNA was similar to the interaction found between serum
HBsAg and HBV DNA in previous studies [20,21]: moderate
correlation in HBeAg-positive disease, but a weaker corre-
lation in HBeAg-negative disease (Table 2A). This signiﬁes
serum HQ-HBsAg, with its advantages of a lower limit of
detection and theoretically better detection of mutations
compared with the ‘a’ determinant, could potentially replace
serum HBsAg measurements in disease monitoring and
prognostication. Serum HQ-HBsAg is signiﬁcantly higher
than HBsAg in HBeAg-positive disease, possibly due to
the enhanced detection of minor viral populations with
‘a’ determinant mutations in patients with higher viral
loads [11].
Serum HBcrAg has been previously shown to correlate
strongly with intrahepatic markers of viral activity [14]. In our
present study, besides demonstrating good correlation with
serum HBV DNA in all disease phases, we found that HBcrAg
might be a good virological marker to be used to differentiate
HBeAg-negative patients with active and inactive disease, as
illustrated by the large difference of median values observed
between the ENH group and the ENQ group, (4.92 and 2.60
log U/mL, respectively, a 2.3 log difference) (Table 1, Fig. 1d).
In addition, 42.1% of patients in the ENQ group had
undetectable HBcrAg. These results indicate that HBcrAg
production is signiﬁcantly lower in disease-quiescent
HBeAg-negative patients compared with disease-active
HBeAg-negative patients. It would hence be interesting to
investigate whether there is any threshold HBcrAg level that
could predict subsequent HBsAg seroclearance, as seen in the
case of low HBsAg levels [8]. Another possible role for
HBcrAg would be in the prediction of HCC [15,22], which
could be explained by its good correlation with serum HBV
DNA, and it potentially could complement well-established
risk models for HCC [23,24].
An important ﬁnding of our study is the detectability of
HQ-HBsAg and HBcrAg among 40% of CHB patients
achieving HBsAg seroclearance, validating the results of our
previous study [16]. The cumulative rate of HBsAg seroclea-
rance has been reported to be 12.5% [25], with the
seroclearance rate increasing after the age of 40 years [26].
Despite HBsAg seronegativity, these individuals would still
harbour occult HBV infection, with intrahepatic HBV DNA
present at low replicative levels after HBsAg seroclearance
[9], and could still develop HCC [27] and fulminant reacti-
vation during immunosuppressive therapy [9,28,29]. Since
HQ-HBsAg and HBcrAg apply different virological methods in
detecting HBV, their combined use could cumulatively
improve the identiﬁcation and differentiation of occult HBV
infection from those with only past HBV exposure, allowing
these individuals to beneﬁt from HCC surveillance pro-
grammes or closer viral monitoring during immunosuppres-
sion.
Our study results may lay the foundation for the applica-
bility of serum HQ-HBsAg and HBcrAg during peginterferon
or NA therapy. Both markers could display on-treatment
kinetics, which could affect treatment decisions, similar to
HBsAg levels during peginterferon therapy [17]. Although
most patients would require long-term NA therapy to
achieve continued virological suppression, treatment cessa-
tion after HBsAg seroclearance, seen in a minority of
patients, has been shown to be durable [30]. The role of
HQ-HBsAg, with its lower detection limit, in deﬁning the
optimal time-frame for treatment cessation hence warrants
further investigation.
Our study is limited by its cross-sectional nature, but
longitudinal studies may be difﬁcult given that patients in the
IC and ENH groups are candidates for treatment. Our study
also only included genotype B and C patients and, because
HBsAg kinetics display inter-genotypic variability [17,21],
future studies should include patients with other HBV
genotypes.
In conclusion, our study’s two novel markers, serum
HQ-HBsAg and HBcrAg, demonstrated a high degree of
correlation with traditional viral markers in different dis-
ease phases of CHB. Unique patterns of serological distri-
bution are present, including the combined 40% detectability
among CHB patients with HBsAg seroclearance. These
results may lay the foundation for future longitudinal studies
investigating their applicability in both untreated and treated
CHB.
TABLE 3. Potential advantages of applying HBcrAg and
HQ-HBsAg in clinical practice
HBcrAg HQ-HBsAg
Proven
Correlate strongly with disease activity Lower HBsAg detection limit
Differentiate ENQ and ENH groups
in HBeAg-negative disease
Better detection of HBsAg mutants
Detect occult HBV infection Detect occult HBV infection
Potential (needs further evaluation)
Predict occurrence of HCC Replace conventional serum HBsAg
quantiﬁcation
Predict HBsAg seroclearance Better delineation in durability
of NA treatment cessation
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